🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

Liquidia Corp's chief business officer sells shares worth $5,190

Published 10/29/2024, 05:17 PM
LQDA
-

MORRISVILLE, N.C.—Jason Adair, Chief Business Officer of Liquidia Corp (NASDAQ:LQDA), has sold 459 shares of the company's common stock, according to a recent SEC filing. The shares were sold at an average price of $11.3081 each, totaling approximately $5,190.

The transaction, executed on October 28, 2024, was conducted under a Rule 10b5-1 trading plan, which Adair adopted on December 15, 2023. This plan allows insiders to set up a predetermined schedule for selling stocks to avoid potential conflicts of interest.

The shares sold were part of a strategy to cover taxes associated with the settlement of restricted stock units (RSUs) granted to Adair on July 6, 2023. Following this transaction, Adair holds 118,115 shares of Liquidia Corp, which includes unvested RSUs and shares acquired through the company's 2020 Employee Stock Purchase Plan.

In other recent news, Liquidia Technologies (NASDAQ:LQDA) has seen significant developments. The company's product, Yutrepia, received tentative approval from the FDA for the treatment of Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension in patients with Interstitial Lung Disease (PH-ILD). This approval follows the Supreme Court's decision to invalidate the '793 patent challenge by United Therapeutics (NASDAQ:UTHR) Corporation, removing legal obstacles for Liquidia. However, another patent dispute involving the '327 patent still looms over the company's ability to launch Yutrepia in the PH-ILD market.

Analysts at LifeSci Capital and BTIG maintain their positive outlook on Liquidia, reaffirming their Outperform and Buy ratings respectively. Despite a decrease in Q2 2024 revenue, down to $3.7 million from $4.8 million in the same period last year, Liquidia maintains a cash reserve of $133 million and has secured approximately $100 million for cardiopulmonary drug development.

Furthermore, Liquidia is involved in legal challenges, facing a renewed lawsuit from United Therapeutics Corporation, and has initiated legal proceedings against the FDA over the agency's grant of a 3-year new clinical investigation exclusivity to United Therapeutics' drug Tyvaso DPI. These are among the recent developments for Liquidia Technologies.

InvestingPro Insights

As Jason Adair's recent stock sale unfolds, investors may find additional context in Liquidia Corp's financial landscape. According to InvestingPro data, Liquidia's market capitalization stands at $930.94 million, reflecting its current position in the biotech sector. Despite the company's robust market presence, InvestingPro Tips highlight that Liquidia is not expected to be profitable this year, which aligns with the broader financial picture of many developmental-stage biotech firms.

Interestingly, while the company faces profitability challenges, it has demonstrated a strong return over the last year, with a 1-year price total return of 77.9%. This performance suggests investor optimism about Liquidia's potential, possibly tied to its pipeline developments or market positioning.

Another relevant InvestingPro Tip indicates that Liquidia operates with a moderate level of debt, which could provide financial flexibility as the company navigates its growth trajectory. This financial prudence may be reassuring to investors in light of the company's current unprofitability.

For those seeking a deeper understanding of Liquidia's financial health and market position, InvestingPro offers 11 additional tips, providing a comprehensive view of the company's prospects and challenges.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.